TD Cowen raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $205 from $195 and keeps a Buy rating on the shares. The firm said Q4 revenue came in above consensus supported by solid performance from Jazz’s oxybate business as well as Epidiolex.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals: Strong Buy Rating Backed by Robust Financial Performance and Strategic Growth Initiatives
- Jazz Pharmaceuticals price target raised to $167 from $162 at Baird
- Positive Outlook for Jazz Pharmaceuticals: Strategic Wins and Promising Financial Projections Lead to Buy Rating
- Jazz Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating
- Jazz Pharmaceuticals Reports Strong 2024 Financial Results